DMK Pharmaceuticals (DMK Pharmaceuticals) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2023)

View and export this data going back to 1995. Start your Free Trial

What is DMK Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. DMK Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Sep. 2023 was 0.00.

DMK Pharmaceuticals's long-term debt to total assets ratio declined from Sep. 2022 (0.01) to Sep. 2023 (0.00). It may suggest that DMK Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

DMK Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for DMK Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMK Pharmaceuticals LT-Debt-to-Total-Asset Chart

DMK Pharmaceuticals Annual Data

Trend

Mar13

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.05

0.01

DMK Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	-	-	-	-

DMK Pharmaceuticals LT-Debt-to-Total-Asset Calculation

DMK Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )	/	Total Assets (A: Dec. 2022 )
	=	0	/	10.931
	=	0.00

DMK Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (Q: Sep. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2023 )	/	Total Assets (Q: Sep. 2023 )
	=	0	/	8.957
	=	0.00

DMK Pharmaceuticals (OTCPK:DMKPQ) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

DMK Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of DMK Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (OTCPK:DMKPQ) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130

Website

https://www.adamispharmaceuticals.com

DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

Executives

Dorbin John W. Jr.	officer: General Counsel	C/O ARCIMOTO, INC., 2034 WEST 2ND AVENUE, EUGENE OR 97402
Seth Cohen	officer: CFO	C/O NEWTEK BUSINESS SERVICES,INC, 1440 BROADWAY, NEW YORK NY 10018
Ebrahim Versi	director, officer: CEO	11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Jannine Versi	director	11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Vickie S Reed	director	TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037
David J. Marguglio	director	2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Carlo Dennis J Phd	director, 10 percent owner, officer: President/CEO	PO BOX 1176, RANCHO SANTA FE CA 92067
Ronald B. Moss	officer: Chief Medical Officer	11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
David C. Benedicto	officer: Chief Financial Officer	11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Meera J. Desai	director	1682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Robert O Hopkins	officer: Chief Financial Officer	2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Karen K. Daniels	officer: Vice President of Operations	11455 EL CAMINO REAL, SUITE 310, SAN DIEGO CA 92130
Howard C Birndorf	director	C/O NANOGEN INC, 10398 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Roshawn A. Blunt	director	11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Richard C Williams	director	26001 OSPREY NEST COURT, BONITA SPRINGS FL 34134